Science
Strong topical literature, thin injectable data — a compound with a genuinely split evidence base.
GHK-Cu is unusual among the compounds we cover: decades of dermatological literature support topical use, while the injectable use discussed in community spaces rests on almost no direct evidence.
The topical evidence includes controlled comparisons against established actives on photoaging endpoints. The injectable literature, by contrast, consists mostly of mechanism extrapolation from wound-healing models. Researchers should treat the two routes as different evidence questions entirely.
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchAngiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.
ScienceSURMOUNT-5 and real-world cohorts consistently favor the dual agonist on weight endpoints — with nuances the headlines skip.
ResearchThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
